Cannabis
Also known as: Blunt, Bud, Dope, Ganja, Grass
Methodology & AI Transparency ⓘ
Cannabis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cannabis? Cannabis, also known as marijuana, is a green, brown, or gray mixture of dried parts from the cannabis plant.
- 2 Real-world patient consensus: Diagnostic registry F90.1: Cannabis is managed within ADHD & Focus (aka Blunt).
- 3 Typical cash cost range: Clinicians assessing Cannabis focus on default-mode network intrusion [Cannabis F90.1] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Cannabis: ASRS-v1.1 / Vanderbilt in Cannabis (F90.1: Executive Score) (Functional symptom control (F90.1)) and Resting Blood Pressure in Cannabis (F90.1: & Pulse (on).
Ask our AI Specialists anything about Cannabis
What Is Cannabis?
What is cannabis? Cannabis, also known as marijuana, is a green, brown, or gray mixture of dried parts from the cannabis plant. The plant contains chemicals that affect the brain and can change how you feel or think. The main active chemicals are cannabinoids, including: THC (tetrahydrocannabinol), which causes the "high" CBD (cannabidiol), which does not cause a high How do people use cannabis? There are many ways that people use cannabis, including: Rolling it up and smoking it like a cigarette ("joint") or cigar ("blunt") Smoking it in a pipe ("bowl") or water pipe ("bong") Mixing it into drinks like tea, or food like cakes or brownies ("edibles") Smoking concentrated.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Cannabis (ICD-10 F90.1) is driven by default-mode network intrusion [Cannabis F90.1]; Cross-referenced with NIH MeSH (Marijuana Use, Medical Marijuana), specialists in ADHD, Autism & Behavioral Health monitor Resting Blood Pressure in Cannabis (F90.1: & Pulse (on) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • THC (tetrahydrocannabinol), which causes the "high"
- • CBD (cannabidiol), which does not cause a high
- • Presentation of Cannabis (F90.1): time blindness, working-memory in Cannabis (F90.1: slips, and chronic)
- • Secondary Cannabis clinical sign: internal restlessness, impulsive in Cannabis (F90.1: interrupting, or emotional)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cannabis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F90.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | ADHD, Autism & Behavioral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ASRS-v1.1 / Vanderbilt in Cannabis (F90.1: Executive Score) | Functional symptom control (F90.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Blood Pressure in Cannabis (F90.1: & Pulse (on) | < 125/80 mmHg; HR < 85 bpm (F90.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Cannabis (F90.1: Iron Saturation) | Ferritin 50 – 120 ng/mL (F90.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cannabis
Treatment selection for Cannabis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cannabis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on NTI164, a novel medicinal cannabis extract, improves core symptoms of autism NTI164 significantly improved core and associated symptoms of ASD compared to placebo. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42561512 ↗ |
| Managing Alcohol Use Disorder: Can Once-Weekly Semaglutide Make a Real Difference? (What New Research Reveals) Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized. JAMA psychiatry • 2025-04-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39937469 ↗ |
| Managing Trouble sleeping: Can Medicinal cannabis improves sleep Make a Real Difference? (What New Research Reveals) Observed effects were more pronounced in Phase 2 due to the period effect and loss of blinding. Journal of sleep research • 2023-06-15 • Randomized Controlled Trial | N = 29 | 88/100 | PMID 36539991 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Results: CBD showed no difference in relationship to placebo for primary and secondary outcomes. Cannabis and cannabinoid research • 2023-04-15 • Phase III Randomized Trial | N = 18 | 88/100 | PMID 35749710 ↗ |
Cannabis Patient Community & “People Like Me” Threads
Filter Cannabis community threads and patient logs by age, biological sex, dosage, and treatment duration.